ISTH 2024 Reveals Late-Breakthrough Abstracts for Bangkok Presentation

The International Society on Thrombosis and Haemostasis (ISTH) has announced that the 2024 ISTH Congress will be held in Bangkok, Thailand, from June 22 to 26. This significant event marks the return of the Congress to the Asia-Pacific region for the first time since 2011, when it was hosted in Kyoto, Japan. Notably, it will be the first time the Congress is convened in Bangkok.

The ISTH 2024 Congress will bring together thousands of preeminent experts in the fields of thrombosis, hemostasis, and vascular biology. These specialists will present groundbreaking advancements, share the latest scientific discoveries, and discuss new clinical applications aimed at enhancing patient care. The Congress promises an extensive range of educational sessions, poster and oral presentations, state-of-the-art lectures, and exhibits from the medical industry, fostering professional networking and the exchange of cutting-edge scientific knowledge.

One of the highlights of the Congress will be the presentation of late-breaking abstracts, which cover significant recent developments in the field. Some of the key studies to be presented include:

1. Evaluation of recombinant human prourokinase in the treatment of acute pulmonary embolism (ERUPTE). This randomized, single-blinded, multicenter, phase 2 trial will be presented by Zhi-Cheng Jing from Guangdong Provincial People's Hospital, China.
2. Efficacy and safety of Mim8 prophylaxis in adults and adolescents with hemophilia A with or without inhibitors. The phase 3, open-label, randomized, controlled FRONTIER2 study will be shared by Maria Elisa Mancuso from IRCCS Humanitas Research Hospital, Italy.
3. EMA601, a novel humanized fab that inhibits platelet Glycoprotein VI with unprecedented effectiveness, protects mice from arterial thrombosis and ischemic stroke. This study will be presented by Stefano Navarro from the University of Würzburg, Germany.

For a detailed list of all late-breaking abstracts to be presented during the Congress, attendees can review the schedule provided.

On Sunday, June 23, 2024, several noteworthy sessions will occur:
- At 9:30 a.m., David Kuter from Massachusetts General Hospital, United States, will discuss the safety, tolerability, and efficacy of mezagitamab (TAK-079) in chronic or persistent primary immune thrombocytopenia. This will be part of Late Breakthrough Session 1.1 in the Plenary Hall.
- At 9:45 a.m., Ivan Krivega from SonoThera, United States, will present on engineering FVIII protein to enhance its expression and secretion, aiming to achieve normal levels of FVIII in plasma through noninvasive transcutaneous ultrasound mediated gene delivery. This is scheduled for Late Breakthrough Session 1.2 in the Plenary Hall.
- Zhi-Cheng Jing will again present at 10:00 a.m. during Late Breakthrough Session 1.3 in the Plenary Hall, discussing the ERUPTE trial.
- At 10:15 a.m., Stefano Navarro's presentation on EMA601 will take place during Late Breakthrough Session 1.4 in the Plenary Hall.
- Finally, at 10:30 a.m., Maria Elisa Mancuso will discuss the FRONTIER2 study in Late Breakthrough Session 1.5 in the Plenary Hall.

Due to space constraints, the ISTH 2024 Congress will not host a press conference this year.

The ISTH, founded in 1969, is a leading non-profit organization dedicated to advancing the understanding, prevention, diagnosis, and treatment of thrombosis and hemostasis-related conditions. With over 7,000 members worldwide, ISTH's initiatives include educational programs, clinical and laboratory practice guidelines, research activities, congresses, peer-reviewed publications, expert committees, and the observance of World Thrombosis Day on October 13 each year.